What happens when twins are diagnosed with a life-altering condition like Spinal Muscular Atrophy (SMA)? For Jesy Nelson, the mother of twins Emma and Bartosz, the answer is a journey filled with challenges and advocacy for better healthcare practices. Emma and Bartosz, both diagnosed with SMA type 1—the most severe form of the disease—have brought to light the critical need for early screening of this condition in newborns.
Emma was diagnosed with SMA in 2024, while Bartosz received his diagnosis three years earlier, in 2021. Both children were diagnosed late, which has led to significant mobility issues that they will likely face for life. This late diagnosis is not just a personal tragedy for the Nelson family; it reflects a broader systemic issue in the UK, where an estimated 33 babies each year may need a wheelchair due to similar late diagnoses of SMA.
In response to the growing awareness of SMA’s impact, the Scottish government has announced that all babies will now be screened for SMA as part of the NHS newborn blood spot test. This move is crucial, as early intervention can significantly alter the course of the disease. Emma and Bartosz were fortunate to receive the gene therapy Zolgensma through the NHS, a treatment that can halt the progression of SMA and potentially eradicate it if administered early enough.
What the data shows
The UK currently stands as a global outlier regarding newborn SMA screening, lagging behind 46 countries, including the United States and nearly three-quarters of Europe, where such screening is already in place. The projected rollout year for SMA screening in England is 2031, leaving many families like the Nelsons to navigate the complexities of late diagnosis and treatment in the interim.
Jesy Nelson’s experience is echoed by other families facing similar struggles. Paola and Rhys Davie, who also have children with SMA, expressed their solidarity, stating, “We know how you feel,” and “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” Their words resonate deeply within the SMA community, highlighting the emotional toll of navigating such a diagnosis.
Paola poignantly remarked, “It’s awful to think that if I’d decided to give birth in Italy, we probably wouldn’t be having this conversation,” emphasizing the disparities in healthcare systems across countries. The sentiment reflects a growing frustration among families advocating for better healthcare policies and practices in the UK.
As Emma and Bartosz continue their journey, their family remains hopeful. Rhys Davie shared, “Any moment like that when we can see she’s become stronger is incredible – we just feel so much gratitude and joy.” This sentiment captures the essence of resilience in the face of adversity, as families rally together to advocate for necessary changes in healthcare.
While the future of SMA screening in the UK looks promising, many uncertainties remain. Details remain unconfirmed regarding the exact timeline and implementation of these screening measures. However, the Nelson family’s story serves as a powerful reminder of the importance of early diagnosis and intervention, not just for twins like Emma and Bartosz but for all children at risk of SMA.